Clinical Trial Update: Effects of empagliFlozin on myocardIal metabOlic Rate of glucosE Estimated Through 18FDG PET (FIORE Study) [Phase 4]

View source ↗

Summary

Phase 4 trial update evaluating empagliFlozin effects on myocardial metabolic rate of glucose estimated by 18FDG PET in adults with type 2 diabetes at cardiovas…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiovascular Risk Factors
• Type 2 Diabetes Mellitus

Drugs mentioned

• Empagliflozin (empagliflozin)

Snippet

Sponsor: University of Catanzaro | Conditions: Type 2 Diabetes, Cardiovascular Risk Factor | Phase 4 | Status: COMPLETED